PriceTargets.com logo

Absci - ABSI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.40
  • Forecasted Upside: 87.50%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$4.48 As of 07/26/2024 01:00 AM ET
▲ +0.1 (2.28%)

This chart shows the closing price for ABSI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Absci Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABSI

Analyst Price Target is $8.40
▲ +87.50% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Absci in the last 3 months. The average price target is $8.40, with a high forecast of $13.00 and a low forecast of $6.00. The average price target represents a 87.50% upside from the last price of $4.48.

This chart shows the closing price for ABSI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Absci. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/11/2024KeyCorpLower TargetOverweight ➝ Overweight$8.00 ➝ $6.00Low
7/3/2024Morgan StanleyInitiated CoverageOverweight$7.00Low
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00Low
3/26/2024Truist FinancialReiterated RatingBuy ➝ Buy$9.00Low
3/25/2024ScotiabankReiterated RatingOutperform$13.00Low
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00Low
3/14/2024ScotiabankInitiated CoverageSector Outperform$13.00Low
3/6/2024Truist FinancialReiterated RatingBuy ➝ Buy$9.00Low
3/4/2024KeyCorpBoost TargetOverweight ➝ Overweight$5.00 ➝ $8.00Low
1/8/2024HC WainwrightBoost TargetBuy ➝ Buy$4.00 ➝ $7.00Low
1/5/2024KeyCorpBoost TargetOverweight ➝ Overweight$3.00 ➝ $5.00Low
12/5/2023KeyCorpInitiated CoverageOverweight$3.00Low
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$4.00Low
8/16/2023Truist FinancialReiterated RatingBuy ➝ Buy$10.00Low
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$4.00Low
5/4/2023HC WainwrightInitiated CoverageBuy$4.00Low
8/12/2022JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightLow
8/12/2022Credit Suisse GroupLower TargetOutperform$28.00 ➝ $14.00Low
8/12/2022CowenUpgradeOutperformLow
8/12/2022CowenUpgradeMarket Perform ➝ OutperformLow
7/18/2022Truist FinancialInitiated CoverageBuy$8.00Low
5/31/2022Stifel NicolausLower Target$28.00 ➝ $10.00High
3/23/2022Credit Suisse GroupLower TargetOutperform$29.00 ➝ $28.00High
3/2/2022CowenInitiated CoverageHoldLow
2/1/2022Berenberg BankInitiated CoverageBuy$28.00Medium
11/10/2021Bank of AmericaDowngradeNeutral ➝ Underperform$17.00 ➝ $10.00High
8/16/2021JPMorgan Chase & Co.Initiated CoverageOverweightHigh
8/16/2021Stifel NicolausInitiated CoverageHold$28.00High
8/16/2021UBS GroupInitiated CoverageNeutral$26.00High
8/16/2021Credit Suisse GroupInitiated CoverageOutperform$40.00High
8/16/2021CowenInitiated CoverageMarket PerformHigh
8/16/2021Bank of AmericaInitiated CoverageNeutral$26.00High
(Data available from 7/26/2019 forward)

News Sentiment Rating

1.14 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/29/2023
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 2 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
3/28/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
5/27/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024

Current Sentiment

  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Absci logo
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Read More

Today's Range

Now: $4.48
Low: $4.38
High: $4.54

50 Day Range

MA: $3.92
Low: $2.92
High: $4.96

52 Week Range

Now: $4.48
Low: $1.11
High: $6.72

Volume

735,203 shs

Average Volume

1,528,313 shs

Market Capitalization

$506.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Absci?

The following Wall Street research analysts have issued reports on Absci in the last year: HC Wainwright, KeyCorp, Morgan Stanley, Scotiabank, and Truist Financial Co..
View the latest analyst ratings for ABSI.

What is the current price target for Absci?

5 Wall Street analysts have set twelve-month price targets for Absci in the last year. Their average twelve-month price target is $8.40, suggesting a possible upside of 87.5%. Scotiabank has the highest price target set, predicting ABSI will reach $13.00 in the next twelve months. KeyCorp has the lowest price target set, forecasting a price of $6.00 for Absci in the next year.
View the latest price targets for ABSI.

What is the current consensus analyst rating for Absci?

Absci currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABSI will outperform the market and that investors should add to their positions of Absci.
View the latest ratings for ABSI.

What other companies compete with Absci?

Other companies that are similar to Absci include Harpoon Therapeutics, TScan Therapeutics, Sutro Biopharma, Adaptimmune Therapeutics and Tenaya Therapeutics. Learn More about companies similar to Absci.

How do I contact Absci's investor relations team?

The company's listed phone number is 360-949-1041 and its investor relations email address is [email protected]. The official website for Absci is www.absci.com. Learn More about contacing Absci investor relations.